This technology is a microplate assay that enables therapeutic screening and dosage optimization of compounds directly on porcine or patient tissue.
Drug and compound screening to treat diseases targeting pleural and peritoneal membranes (such as the bladder) require an understanding of more than just the efficacy of the drug on the pathogenic disease pathway in isolated cells. However, most in vitro cancer models employ tumor spheroids for drug screening that are limited by non-uniformity, low yield, and insufficient approximation of the complex tumor microenvironment. Particularly for assessing radioactive isotopes, there is a need for a drug screening method that reports on penetration depth, degree of leakage, and extent of tissue damage, parameters tied to therapeutic efficacy and adverse side effects.
This technology is a microplate assay platform that can be used to test efficacy and determine dosage of chemotherapeutics such as radioisotopes. Unlike assays that rely on cell spheroids, this technology employs explanted tissue samples that are easily harvested from porcine bladders or resected human tissues. The tissue samples are then pressed into a 24-well plate to enable rapid in vitro evaluation of bladder cancer drug candidates, and can be subsequently processed for further biochemical, genetic, or histologic analyses. As such, this technology offers an efficient and cost-effective method for in vitro chemotherapeutic drug screening that better approximates in vivo administration.
This technology has been validated through the screening of compounds targeted for bladder cancer.
Herbert Irving Comprehensive Cancer Center, Division of Hematology/Oncology
Patent Pending
IR CU17283
Licensing Contact: Jerry Kokoshka